S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Advaxis Provides 2014 Year-End Review and 2015 Outlook|
|Advaxis to Host Analyst & Investor Day on February 3, 2015|
|Advaxis's Listeria-based Lm-LLO Immunotherapy Featured in Nature Biotechnology|
|Advaxis to Present Survival Data of Lm-LLO Cancer Immunotherapies in Recurrent Cervical Cancer and Canine Osteosarcoma at the Society for Immunotherapy of Cancer 29th Annual Meeting|
|Advaxis's Lm-LLO Immunotherapy Data to be Presented in Three Posters at the Society for Immunotherapy of Cancer 29th Annual Meeting|
|Advaxis Submits Investigational New Drug Application for ADXS31-142 (ADXS-PSA) for the Treatment of Metastatic Castration Resistant Prostate Cancer|
|Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence Clinical Trials of ADXS-PSA in Combination With Merck's KEYTRUDA(R) (pembrolizumab) for Prostate Cancer|
|Advaxis's Cancer Immunotherapies Featured on FOX News|
|Advaxis Submits Investigational New Drug Application for Phase 1/2 Study of ADXS-HPV and MedImmune's MEDI4736 for the Treatment of HPV-Associated Cervical and Head & Neck Cancer|
|Advaxis to Receive $1.7M Through New Jersey Technology Business Tax (NOL) Program|
Click above to view more mutual fund data and stats for lm - Lingo Media Corp.